latest
Clinical Articles

Retinal clinical trials indicate that almost 50% of studies have non-compliance issues

Clinical research has indicated that almost half of trial studies have noncompliance issues, creating negative impact outcomes for research.  A recent study has shown that 54.4% of patients were compliant with completing all study visits while 45.6% of subjects were noncompliant.  Given that trials are a cornerstone to collect patient data in order to build […]

Read full story

Phase 1b study of a new anti-VEFG antibody has reported BCVA gains across wet AMD, diabetic macular edema and retinal vein occlusion

A brief clinical update reporting on a new anti-VEGF antibody conjugate polymer (identified as KSI-301) has highlighted visual acuity gains with three indications – wet AMD, diabetic edema and retinal vein occlusion.  The experimental treatment has a novel higher molecular weight antibody moiety -950kDA- considerably larger than other anti-VEGF antibodies (ranibizumab [48kDa] and aflibercept [115kDa]).  […]

Read full story

Real world data has reported the comparison outcomes between ranibizumab (Lucentis) and aflibercept (Eylea) for Diabetic Macular Edema (DME)

A clinical research report, published in the journal Ophthalmology, has found that two leading anti-VEGF treatments had shown beneficial outcomes for DME in a study of real word data.  The study found that both aflibercept (Eylea) and ranibizumab (Lucentis) were effective for DME over 12 months, identifying that aflibercept had somewhat better anatomic outcomes. In […]

Read full story

Related Clinical News